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Vascular tissue engineering
Mesenchymal stem cellsSuccessful implantation and long-term survival of engineered tissue grafts hinges on adequate vascular-
ization of the implant. Endothelial cells are essential for patterning vascular structures, but they require
supportive mural cells such as pericytes/mesenchymal stem cells (MSCs) to generate stable, functional
blood vessels. While there is evidence that the angiogenic effect of MSCs is mediated via the secretion
of paracrine signals, the identity of these signals is unknown. By utilizing two functionally distinct
human MSC clones, we found that so-called “pericytic” MSCs secrete the pro-angiogenic vascular guid-
ance molecule SLIT3, which guides vascular development by directing ROBO4-positive endothelial cells
to form networks in engineered tissue. In contrast, “non-pericytic” MSCs exhibit reduced activation of
the SLIT3/ROBO4 pathway and do not support vascular networks. Using live cell imaging of organizing
3D vascular networks, we show that siRNA knockdown of SLIT3 in MSCs leads to disorganized clustering
of ECs. Knockdown of its receptor ROBO4 in ECs abolishes the generation of functional human blood ves-
sels in an in vivo xenogenic implant. These data suggest that the SLIT3/ROBO4 pathway is required for
MSC-guided vascularization in engineered tissues. Heterogeneity of SLIT3 expression may underlie the
variable clinical success of MSCs for tissue repair applications.
© 2013 The Authors. Published by Elsevier Ltd. Open access under CC BY license.1. Introduction
Cell-based regenerative medicine therapies such as cardiac tissue
engineering for ischemic heart disease require adequate vascularization-L-alanyl-2-phenyl]glycine-1,1-
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ript.
.Open access under CC BY license.for successful implantation and long-term survival [1,2]. Pericytes are
microvascular mural cells which directly interact with endothelial
cells to promote endothelial growth and stabilize endothelial networks
[3–5]. Importantly, pericytes and mesenchymal stem cells (MSCs)
derived from bone marrow or other tissues express a similar array
of cell surface markers, thus suggesting that they have signiﬁcant
functional and phenotypic overlap [6–8].
Like pericytes, MSCs can be combined with endothelial cells to en-
hance the formation of vascular networks [3,9–11]. The currently pro-
posed mechanisms of how MSCs promote angiogenesis are thought to
involve the release of angiogenic growth factors [12,13] and stabiliza-
tion of vascular networks through direct contact. The pericyte function
of MSCs remains poorly deﬁned and it is not known whether MSCs
release mediators of vascular endothelial cells, similar to those released
by pericytes [14]. We sought to explore the contribution of MSCs to EC
vascular network formation in vitro and to highly vascularized tissue
constructs in vivo, as well as deﬁne the role of potential vascular
mediators released by MSCs.
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Fig. 1. Cross-talk between human endothelial cells (ECs) and human mesenchymal stem cells (MSCs) promotes the formation of vascular networks in engineered tissue and perfused
blood vessels in vivo. a, Gross photographs ofwhole gel explants at 7 days illustrate signiﬁcant vascularization of gels containing both cell types by the visible red color in EC:MSC explants
(right). Scale bar: 5 mm. b, Representative hematoxylin & eosin (H&E) stainings of collagen/ﬁbronectin gel explants after 7 days in vivo show minimal vascularization in implants
containing either human ECs (top) or human MSCs (middle). Signiﬁcant vascularization is observed in implants containing a mixture of the two cell types (bottom) in a 1:1 ratio,
where 1 × 106 total cells were implanted per condition. Scale bar: 200 μm, left; 40 μm, right. c, Red blood cell content in vascularized EC:MSC gel plug, measured by immunostaining
against TER-119 (red), is signiﬁcantly increased in EC:MSC plugs as compared to either cell type alone (p b 0.001). Scale bar: 20 μm. Quantiﬁcation of TER-119 positivity is normalized
to the number of DAPI-positive nuclei within each high power ﬁeld (n = 18 (MSC), n = 4 (EC), and n = 16 (EC:MSC)). d, Immunostaining against CD31 (brown, DAB) in representative
scaffold-free engineered tissues after 8 days of in vitro culture containing ECs plus either MSC27a or MSC5 cells shows greatly increased EC networks with MSC27a co-culture. Scale bar:
100 μm.And e, Quantiﬁcation of in vitro vascularization in engineered tissues by automated detection of regions of interest (ROI) from brownCD31 stain shows increased vascular density
(left) and a broader spectrum of structure sizes (right, assessed by individual ROI areas and plotted as a histogram). ROI density is deﬁned as the total number of ROI per area (mm2). ROI
area (μm2) indicates the area of each ROI outlined (see Supplementary Fig. 1) and is binned and plotted as a relative frequency of the total number of structures (deﬁned as 1.0). The ROI
area is a surrogate measure for vessel diameter.
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2.1. Cell culture
Adult human aortic endothelial cells (HAECs, Lonza) and human
umbilical vein endothelial cells (HUVECs, Lonza) were maintained
in endothelial cell growth medium-2 (EGM-2, Lonza) according to
the manufacturer's recommendations and no longer than passage
7. Human bone marrow-derived mesenchymal stem cells (MSCs,
Lonza) were maintained in minimal essential medium (α-MEM,
Invitrogen) supplemented with 16.5% FBS, 2 mM L-glutamine, and
penicillin/streptomycin (ﬁnal concentration 100 units/ml penicillin
and 100 μg/ml streptomycin). MSCs were passaged no more than
twice after being thawed before being used in experiments. Human
marrow stromal cell clones HS-5 (MSC5) and HS-27a (MSC27a)
[15] were cultured in Dulbecco's modiﬁed Eagle medium (DMEM,
Gibco) with 5% fetal bovine serum (FBS) and 2 mM L-glutamine.
2.2. Generation of scaffold-free engineered vascular tissue
Cells were harvested and mixed in a 2:1 ratio (HUVECs:MSCs)
without exogenous extracellular matrix proteins to form scaffold-freeengineered vascular tissue. Tissue patches were formed in ultra-low
attachment six-well plates (Corning) on a rotating orbital shaker
at 40 rpm at 37 °C in 50/50 v/v EGM2 and a high-serum medium
of KO-DMEM (Gibco) with 20% FBS, 1 mM L-glutamine, 0.1 mM
β-mercaptoethanol, and 1% non-essential amino acids as previous-
ly described [11,16]. Disk-shaped engineered tissues (circular and
about 400 μm thick) formed by hydrodynamic forces and cell adhesion
within 2 days andwere cultured for up to 8 days withmedium changes
every other day. Growth factors and small molecule inhibitors were
added freshwithmedia changes and included: recombinant humanvas-
cular endothelial growth factor (VEGF165, 10 or 100 ng/mL; Millipore)
and/or N-[(3,5-Diﬂuorophenyl)acetyl]-L-alanyl-2-phenyl]glycine-1,1-
dimethyletheyl ester (DAPT, a gamma-secretase inhibitor, 0.2, 2, or
20 μM; Tocris Bioscience). Dimethyl sulfoxide (DMSO, up to 0.1%) was
used as a negative control in experiments requiring DMSO as a solvent
for small molecule inhibitors.
2.3. Preparation of cellularized three-dimensional gels
For in vitro and in vivo gel experiments, 3D gels were prepared as
previously described [17]. Brieﬂy, gel components were placed on ice
and combined to the following ﬁnal concentrations: HEPES, 25 mM;
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Fig. 2.MSCs direct ECmovement within primitive vascular networks. a, Live cell imaging of collagen/ﬁbronectin gels containing ECs (red) andMSCs (green) show formation of primitive
vascular structures after 5 days (D5) by ECs in close contactwithMSCs (a heterogeneousMSC population from Lonza). See Supplementary Video 1 for time-lapse video. Scale bar: 250 μm.
b, Time lapse confocal images of an in vitro gel illustrate extensive MSC spreading, MSC cell contact, and EC orientation along MSCs from baseline to day 5 (D5). ECs migrate along MSCs,
shown by white arrows which follow an individual EC over time as it migrates along MSCs on day 2 (D2). Scale bar: 100 μm. c, Three-dimensional cell-tracking images taken over a 16 h
time period on day 5–6 of EC:MSC in vitro gels. Red and green spheres indicate individual ECs andMSCs, while colored tracks indicate the path of cellmovement over time. EC track length
and velocity data are derived from these experiments. d, Velocity (μm/h) of EC movement is signiﬁcantly increased in the presence of MSCs (***P b 0.001). And e, ECs assume a more
elongated phenotype (where a line is deﬁned as 1.0 and a circle is 0.0) within vascular networks when co-cultured with MSCs at both 2 and 5 days (***P b 0.001).
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(Millipore), 100 μg/mL; rat tail collagen type I (Millipore), 1.5 mg/mL;
and EBM-2 supplementedwith 10% FBS and 1% penicillin/streptomycin,
to bring solution to 0.7 × total volume. Gel pHwas adjusted to 7.4 with
1 N NaOH. 1 × 106 total cells (either alone or at a 1:1 ratio of HAECs
and MSCs) were then resuspended in warm EGM-2 medium and
mixed with the ice-cold gel solution at a ratio of 2.3:1 (gel:resuspended
cells), and immediately plated in glass bottom dishes for analysis by
confocal microscopy (ﬁnal volume 1 ml) or into 24-well dishes (ﬁnal
volume 500 μl) and allowed to polymerize for 15–20 min prior to addi-
tion of warm EGM-2 to cover gels for later use in vivo. For in vitro
cell tracking experiments, HAECs were labeled with Celltracker™Red
CMPTX (Invitrogen) and MSCs labeled with Celltracker™ Green
CMFDA (Invitrogen) prior tomixture within gels permanufacturer pro-
tocols. All polymerized gels containing cells were placed in an incubator
at 37°C overnight prior to conducting in vivo experiments.
2.4. Microarray experiments and data analysis
Cellular RNA was harvested from engineered vascular tissue using
the RNeasy Mini Kit (Qiagen) with β-mercaptoethanol (1:100) in RLT
buffer and on-column DNA digestion, then stored at−80 °C until fur-
ther use. RNA ampliﬁcation and labeling was done using the Illumina®
TotalPrep™ RNA Ampliﬁcation Kit (Ambion, Applied Biosystems)
according to the manufacturer's instructions. Two biological replicates
were run per sample. Samples were human MSC HS-5 (MSC5) and
MSC HS-27a (MSC27a) cells (where RNA was harvested from plated
cells) and bi-cell patches with HUVECs and either MSC5 or MSC27a
cells (with RNA collected after 8 days of culture in engineered tissues).
Whole genome expression analysis was performed using theHumanHT-12 V3 BeadChip (Illumina). Expression intensity data was
processed with the GenomeStudio Gene Expression Module (Illumina)
with background subtraction, and then imported into R/Bioconductor
(version 2.15.0 (2012-03-20); R Development Core Team (2012). R: A
language and environment for statistical computing. R Foundation
for Statistical Computing, Vienna, Austria. ISBN 3-900051-07-0, URL
http://www.R-project.org/) for quantile normalization with the
quantile.normalize function in the preprocessCore library (Bolstad,
B.M. PreprocessCore: A collection of pre-processing functions. R pack-
age version 1.18.0), log transformation, and displaywith the heatmap.2
function of the gplots library (Warnes, G.R. gplots: Various R program-
ming tools for plotting data. R package version 2.10.1. http://CRAN.R-
project.org/package=gplots). Fold enrichment was calculated as EC:
MSC27a/EC:MSC5 expression levels for bi-cell tissue patches to exam-
ine gene expression differences in engineered vascular tissue. Microar-
ray data in both cultured cells and in engineered tissues was validated
by qPCR for the genes SLIT3 and ROBO4. Microarray data are MIAME
compliant, and can be accessed in NCBI's Gene Expression Omnibus
[18] with GEO Series accession number GSE48302 (http://www.ncbi.
nlm.nih.gov/geo/query/acc.cgi?acc=GSE48302).
2.5. RNA isolation and gene expression proﬁling
RNAwas isolated frommonolayer cells or 3-dimensional gels using a
Purelink™ RNA Mini Kit (Invitrogen). Dispersion of 3-dimensional gels
was accomplished by vortexing in lysis buffer until the gel was
completely dissolved. cDNA was synthesized using the High Capacity
cDNA Reverse Transcription Kit (Applied Biosystem). RNA was isolated
from engineered tissues using the RNeasy Mini Kit (Qiagen) with β-
mercaptoethanol (1:100) in RLT buffer and on-column DNA digestion.
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Fig. 3.MSC27a cells exhibit a pericytic phenotype, andmanipulation of known angiogenic
pathways does not signiﬁcantly affect vascular formation in engineered tissue constructs.
a, Array expression data heatmap of pericyte and EC markers in two distinct MSC clones
(MSC5 andMSC27a) and in corresponding engineered tissues also containing ECs (labeled
with “gene name (protein)”) shows a general trend towards increased expression in EC:
MSC27a tissues. Scale indicates highly expressed (red) or minimally expressed (blue)
genes based on a row-level z-score calculated as (x–xmean)/StDev (where values are
expressed as log2). Gray color indicates expression was not detected. Note that CD144
and CD31 were highly expressed in EC:MSC27a patches compared to EC:MSC5 patches,
likely due to improved EC survival in the former engineered tissues. And b, Manipulation
of known angiogenic pathways VEGF and NOTCH in engineered tissueswith VEGF-A165 at
10 or 100 ng/ml (10 V or 100 V), orwith 10 ng/ml VEGF-A165 andDAPT at 0.2, 2, or 20 μM
(10 V + 0.2D, 2D, or 20D, respectively) showed no changes in vessel structure
development after 8 days in culture (n = 3 per group, P = not signiﬁcant by ANOVA).
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III Reverse Transcriptase (Invitrogen). Real-time qRT-PCR analysis was
performed using a 7900HT Fast Real-Time PCR System (Applied
Biosystems) using either SYBR®-Green or TaqMan® based detection
systems (Applied Biosystems). Data were normalized to B2M or
HPRT1 expression (endogenous control) and fold changes in gene
expression were determined by the 2−ΔΔCT method. PCR primer
sequences are available upon request.
2.6. Confocal microscopy/time lapse videos
3D gels were imaged with a Zeiss 510META confocal laser scanning
microscope (Carl Zeiss Microimaging, Thornwood, NY, USA) equipped
with an environmental chamber to maintain humidity, temperature
(37 °C) and CO2 (5%). CellTracker Green was excited at 488 nm and
CellTracker Red was excited at 561 nm. Excitation and acquisition at
both wavelengths were carried out simultaneously to minimizemotion
artifact. To be able to image cells in the entire thickness of the gel, a long
working distance 10×/0.30 NA Plan-Neoﬂuar objective was selected
(Zeiss Microimaging). To prevent photobleaching, low laser power,
high scan speed and only 2 scans for averaging were used. Otherimaging parameters were adjusted to optimize the trade-off between
imaging time and spatial resolution. When recording time-lapse
videos for network development, z-stacks were generated every
32 min (1024 × 1024 × 80 sample size, 0.879 × 0.879 × 5.8 μm3
voxel size). The resolution was increased when stacks were
recorded for co-localization analyses (1024 × 1024 × 60 sample
size, 0.879 × 0.879 × 3.53 μm3 voxel size or 2000 × 2000 × 55
sample size, 0.45 × 0.45 × 2.81 μm3 voxel size). High-resolution
images from gels were acquired with a 40×/1.1NA water immersion
objective (0.112 × 0.112 μm2 pixel size) (Zeiss Microimaging).
Imaris 3D/4D image processing and analysis software (Bitplane
Inc., South Windsor, CT) was used for automated tracking of endo-
thelial cells and for 3D co-localization analysis. EC/MSC co-
localization was determinedwith thresholdedMander's coefﬁcients.
2.7. Cell transplantation
All animal experiments were approved by the Institutional Animal
Care and Use Committee (IACUC) of the University of Chicago. Gels
containing 1 × 106 total cells were subcutaneously implanted bilateral-
ly into the ventral surface of adult female NOD SCIDmice after overnight
incubation. To accomplish this, mice were anesthetized with isoﬂurane
and the implantation site cleaned and shaved. A small subcutaneous
pocket was made for each gel, and the wound closed using skin staples.
After 7 days, animals were sacriﬁced, and the gel implants were
harvested.
2.8. Statistical analysis
Data was analyzed by using a Student's unpaired t test or one-way
analysis of variance (ANOVA). P values b0.05 were considered statisti-
cally signiﬁcant.
See Online Data Supplement–Methods for details on cell surface
marker analysis, siRNA transfection, proliferation assays, and
immunohistochemistry.
3. Results
We began by studying angiogenesis in an in vivo model where
human cells were implanted subcutaneously in a collagen/ﬁbronectin
gel. Delivery of either endothelial cells or bone marrow MSCs alone
resulted in minimal vascular network formation, whereas combining
human MSCs and human ECs resulted in profound vascularization
(Fig. 1a,b). The functionality of blood vesselswas assessed bymeasuring
the red blood cell content in the explanted tissues. Tissues containing
both ECs and MSCs showed more than a 15-fold enhancement of red
blood cell content (Fig. 1c). Thus, MSC–EC co-culture robustly supports
vascularization in this in vivo angiogenesis model.
In order to study vascular development and EC–MSC interactions,
we used in vitro engineered tissue patches formed without exogenous
scaffold materials so that they maintain a high cellular density [11].
While the in vivo implantswere performedwith commercially available
MSCs (Lon–MSCs, Lonza), for these in vitro studies we exploited two
human bone marrow-derived MSC clones (HS-27a, designated here as
“MSC27a” and HS-5, designated here as “MSC5”). These clones have
been previously characterized as having distinct functional effects:
MSC5 cells have a ﬁbroblastic growth pattern and support proliferation
of hematopoietic progenitors in co-culture, whereas MSC27a cells grow
in an epithelioid pattern and do not support hematopoietic expan-
sion.[19,20] In engineered tissue patches with ECs and MSCs, only
the MSC27a line was able to support the formation of dense EC net-
works with a broader range of vessel structure sizes (Fig. 1d,e and
Supplementary Fig. 1). Engineered tissue patches with ECs and MSC5
cells had a low density of vessel structures with a more narrow size
range. This ﬁnding not only points to the pericytic nature of MSC27a
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propensity to promote vascular network formation.
We next followed EC:MSC vascular network formation over 5 days
in 3D collagen/ﬁbronectin gels to track the behavior of individual cells
using time-lapse confocal microscopy (Fig. 2a). After 2 days, Lon–
MSCs (green) and ECs (red) remained widely distributed within the
gel, and by day 5, ECs oriented along tracks created by MSCs. Live cell
imaging revealed signiﬁcant movement of ECs along these scaffold-
like tracks (Fig. 2b, Supplementary Video 1). The velocity of EC move-
ment over time was quantiﬁed, and the presence of MSCs signiﬁcantly
enhanced the speed of EC movement at both 2 and 5 days (Fig. 2c,d).
The morphology of ECs also changed in the presence of MSCs, with
ECs becoming signiﬁcantly more elongated and less circular by day 5
in the presence of MSCs (Fig. 2e).
Interestingly, examination of clonal MSC lines showed that MSC27a
cells express relatively higher levels of most classic pericyte markers
such as NG2 and PDGFRB, when compared to the MSC5 cells (Fig. 3a,
Supplementary Table 1). When the MSC lines were combined with
ECs in engineered tissue patches, this difference was even further
enhanced with marked upregulation of the pericyte marker CD73 in
EC:MSC27a tissue patches. On the other hand, MSC5 cells not only
expressed lower levels of most pericyte markers, but they did not
augment the expression of these genes upon combination with ECs. To-
gether, these data suggest that ECs inﬂuence the maturation of MSC27a
cells into vascular pericytes, but ECs andMSC5 cells exhibit less synergy.
The heterogeneous Lon–MSCs expressed surface markers that are typi-
cally found on both MSCs and pericytes (Supplementary Fig. 2a),conﬁrming the presence of at least some pericyte-like cells in this
mixed population.
To better understand what controls vessel formation in engineered
tissue, we assessed vascular structure formation after addition of
known angiogenic factors. Addition of VEGF and inhibition of NOTCH
signaling with a small molecule γ-secretase inhibitor (DAPT) did not
have any signiﬁcant impact on the formation of vascular structures in
engineered tissue containing either MSC5 or MSC27a cells (Fig. 3b).
These data suggested that, althoughVEGF andDAPT can promote angio-
genesis in vitro and in vivo [21], neither VEGF nor inhibition of NOTCH
signaling were sufﬁcient to explain the different abilities of MSCs to
promote vascular network formation in engineered tissue.
Whole genome microarray analysis of MSC clones and EC:MSC
engineered tissue patches was performed to assess differences in MSC
clones and changes in gene expression proﬁles upon co-culture with
ECs. To better understand the pathways involved in the angiogenic con-
tribution of MSC27a compared to MSC5 cells, microarray analysis iden-
tiﬁed 423 genes with N8-fold change in expression (Supplementary
Fig. 2b). Of these, 13 genes were found to be enriched in the gene ontol-
ogies “angiogenesis”, “blood vessel morphogenesis”, “blood vessel
development”, and “vasculature development” by DAVID analysis. The
hierarchical clustering of themicroarray heatmap (Fig. 4a) by similarity
of gene expression proﬁles revealed several key ﬁndings. First, in EC:
MSC27a tissues, there was signiﬁcant upregulation of classic “pro-
angiogenic” genes, such as NOTCH4 and angiopoietin 1 (ANGPT1).
Also clustered in this group and showing the same expression proﬁle
was ROBO4, the endothelial-speciﬁc receptor for SLIT soluble ligands.
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pression levels, for vascular endothelial growth factor A (VEGFA) and
SLIT3, a ligand for ROBO receptors which has also been shown to pro-
mote angiogenesis during organ development [22] (Supplementary
Table 2).
The recently identiﬁed role of the SLIT/ROBO pathway in promoting
angiogenesis during organ development led us to investigate whether
SLIT3–ROBO4 signaling may be an important determinant of vascular
network formation in EC–MSC gels and engineered tissues. In gel assays
containing ECs-only, MSCs-only, or co-cultured ECs and MSCs (in a 1:1
ratio), SLIT3 mRNA was nearly exclusively expressed in MSCs whereas
ROBO4 expression was EC-speciﬁc (Fig. 4b). SLIT3 and ROBO4 expres-
sionwere reduced by about half with co-culture, likely reﬂecting the di-
lution of total mRNA by the mRNA from the other cell type. Increased
expression of SLIT3 in MSC27a as compared to MSC5 cells was con-
ﬁrmedbyqPCR (Fig. 4c), and in engineered tissue patches, SLIT3 expres-
sion was conﬁrmed at the protein level (Fig. 4d), where EC:MSC27a
patches contained intense SLIT3 staining that did not colocalize with
ECs (stained by human CD31). In contrast, EC:MSC5 patches exhibited
minimal staining for SLIT3. The receptor for SLIT3, ROBO4, was
expressed to a higher degree in EC:MSC27a patches as compared to
EC:MSC5 patches (Fig. 4c), possibly due to reduced survival of ECs in
the EC:MSC5 patches. Potential changes in cell numbers during co-
culture were a limitation of this analysis, however the striking differ-
ences in SLIT3 protein levels between MSC5 and MSC27a patches
warranted further investigation. Furthermore, the SLIT3-positiveMSC27a cells appeared to extend processes toward the human CD31-
positive ECs in a pericyte-likemanner (white arrowheads, Fig. 4d), pos-
sibly indicative of a role in maintaining EC structure and function. Ex-
pression of SLIT2, another well-studied SLIT ligand, was not markedly
different between any of the in vivo cell constructs (Supplementary
Fig. 3). Based on these data, we hypothesized that the SLIT3/ROBO4 sig-
naling pathway is active between ECs and MSCs in co-cultured tissues
and controls vascular assembly.
To determine the necessity of SLIT3/ROBO4 signaling inMSC-guided
vessel formation, siRNA knockdown of SLIT3 or ROBO4 was performed.
Sufﬁcient suppression was achieved for SLIT3 (60% reduction) and
ROBO4 (80% reduction; Fig. 5a) andMSC proliferationwas not impacted
by siRNA knockdown of SLIT3 (Supplementary Fig. 4). Instead, suppres-
sion of SLIT3 in MSCs resulted in signiﬁcant aggregation or clustering of
MSCs and ECs in in vitro gel assays at 2 days as measured by 3D
colocalization analysis (Fig. 5b,c). The observed cell clustering suggests
that SLIT3 released by MSCs may act as a repellent in this context, sim-
ilar to its role in neural interactions. This repellent functionmay provide
an important counterbalance to the attractant factors such asVEGF, thus
enabling ECs tomigrate in the three-dimensional gel and to form vascu-
lar networks. The functional importance of SLIT3/ROBO4 was also eval-
uated in vivo. Following siRNA knockdown of either SLIT3 in MSCs or
ROBO4 in ECs, subcutaneous implantation of co-cultured cells in
collagen/ﬁbronectin gels showed a profound suppression of functional
vascularization (Fig. 6). These data demonstrate that SLIT3 and ROBO4
are required for vessel formation in EC:MSC tissues in vitro and in vivo.
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Fig. 6. Inhibition of SLIT3/ROBO4 signaling in vivo leads to signiﬁcantly decreased functional blood vessel formation. a, Perfused vasculature as identiﬁed in H&E stained sections (top) and
by TER119 staining of red blood cells (bottom) in control EC:MSC explants (left) is reducedwith siRNA knockdown of ROBO4 in ECs (EC-siROBO4:MSC,middle) or with siRNA knockdown
of SLIT3 inMSCs (EC:MSC-siSLIT3, right). Scale bar: 200 μm.Andb,Quantiﬁcation of TER119-positive area (normalized to number of nuclei) shows reduced vasculature formation for SLIT3
and ROBO4 knockdown (*P b 0.05).
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Our ﬁndings establish a novel role for the SLIT3/ROBO4 pathway in
engineered vascular tissue and in an in vivo angiogenesis assay where
EC–MSC interactions are required.While this pathway has beenwell de-
scribed in neurovascular guidance [22–26], recent studies also implicate
the SLIT/ROBO pathway in organogenesis, vascular homeostasis, and
tumor angiogenesis [26–29]. It is clear that speciﬁc ligand-receptor
pairs have unique outcomes in different contexts and signal through dif-
ferent mechanisms [30–33]. For example, SLIT2 released from tumor
cells acts as an attractant of ECs for tumor angiogenesis that is ROBO1-
dependent [29]. However, when SLIT2 is bound to ROBO4 in normal vas-
cular homeostasis, this is a stabilizing signal for the vasculature to inhibit
VEGF-induced EC migration, tube formation, and permeability in vitro
and prevent pathologic angiogenesis in the eye [26]. In contrast, when
SLIT3 binds ROBO4, EC motility is stimulated in vitro and angiogenesis
is enhanced in vivo [22]. Further, the SLIT3 knockout mouse displays se-
vere developmental angiogenic defects in the diaphragm [22,28]. Our re-
sults corroborate that SLIT3/ROBO4 modulates angiogenesis via
enhanced EC motility (Fig. 2d), and further suggest that SLIT3/ROBO4
acts to prevent EC aggregation (Fig. 5b,c) andpromote branched pattern-
ing.Most importantly, our results extend the previously established roles
of SLIT/ROBO signaling in tumor angiogenesis or during organ develop-
ment by demonstrating that this pathway may be an important target
in vascular tissue engineering using ECs and MSCs.
The release of SLIT3 fromMSCs that successfully support angiogene-
sis (i.e. MSC27a cells) also suggests that this pathwaymay be indicative
of the pericyte-like phenotype of certain MSCs. Importantly, we ob-
served that MSC clones have distinct SLIT3 expression proﬁles and
vasculogenic potential. MSC27a cells, in addition to producing large
amounts of SLIT3, also express high levels of the pericyte marker NG2(Fig. 3a). Interestingly, when MSC27a cells are combined with ECs,
both the mature MSC marker CD73 and the vascular smooth muscle
cell marker α-smooth muscle actin (SMA) are upregulated (Fig. 3a),
suggesting the presence of a more mature vascular stroma. This syner-
gism between ECs and MSC27a was not seen with ECs and MSC5 cells.
Further, organization of vascular structures in our engineered tissue
constructs, while greatly inﬂuenced by the speciﬁc MSC clone, was not
further affected by manipulation of either VEGF or NOTCH, both recog-
nized to be critical angiogenic factors (Fig. 3b).
While there is signiﬁcant interest in using autologous MSCs for vas-
cular tissue regeneration therapies, variation among patients and prop-
erties of a heterogeneous MSC population need to be considered.
Functional testing of MSCs may be necessary to assess SLIT3 expression
levels and the ability of the MSCs to generate functional vessels in
engineered tissue prior to use of these cells for vascular therapies. Un-
like the immortalized clonal MSC lines such asMSC5 orMSC27a, prima-
ry MSCs obtained from a patient likely represent a heterogeneous
mixture of MSCs, much like the commercially available Lon–MSCs that
were used in this study. The inhibition of vascular network formation
by suppression of SLIT3 in primary MSCs (Fig. 6) demonstrates that
SLIT3/ROBO4 activation is not only important in MSC clones but also
in heterogeneous primary MSCs derived from human subjects or pa-
tients. Such heterogeneous MSC cultures may contain varying fractions
of “pericyte-like”MSCs which support vascular network formation. The
heterogeneous Lon–MSCs exhibited a pericyte phenotype and were
able to promote SLIT3/ROBO4 dependent vascular network formation
in vitro and in vivo, but this may not necessarily apply to all heteroge-
neous MSC populations obtained from patients. Clinical studies may
need to identify whether genetic traits or cardiovascular disease in an
individual can impact the phenotype of MSCs. If MSCs are identiﬁed
that are deﬁcient in SLIT3 or do not have a pericyte-like phenotype,
131J.D. Paul et al. / Journal of Molecular and Cellular Cardiology 64 (2013) 124–131these deﬁciencies may need to be addressed prior to using the cells for
tissue engineering and regenerative therapies.
5. Conclusions
In conclusion, we demonstrate that a pericyte-like function of MSCs
supports the formation of vessel-like structures in vitro and vasculature
in vivo. We show that SLIT3/ROBO4 signaling is required for formation
of EC networks in EC–MSC tissue in vitro and perfused vessels in vivo
in a gel plug angiogenesis assay. Finally, distinct MSC clones show a
baseline variability in expression of SLIT3, suggesting that MSC pheno-
type is an important considerationwhen assessing cells for regenerative
vascular therapies.
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